Normal view MARC view ISBD view

Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.

Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar. - 2014

Available online from MWHC library: 1950 - present, Available in print through MWHC library: 1999 - 2006

English

ISSN: 0009-7322

Subjects--Topical Terms:
*Acute Coronary Syndrome/pc [Prevention & Control]
*Drug Approval
*Lactones/tu [Therapeutic Use]
*Plaque, Atherosclerotic/pc [Prevention & Control]
*Platelet Aggregation Inhibitors/tu [Therapeutic Use]
*Pyridines/tu [Therapeutic Use]
Clinical Trials Data Monitoring Committees
Hemorrhage/ep [Epidemiology]
Humans
Lactones/ae [Adverse Effects]
Platelet Aggregation Inhibitors/ae [Adverse Effects]
Pyridines/ae [Adverse Effects]
Receptor, PAR-1/ai [Antagonists & Inhibitors]
Risk Assessment
United States

Subjects--Geographic Terms:
MedStar Heart & Vascular Institute

Index Terms--Function:
Congresses